Daniel Campbell - Nu Skin Lead Independent Director

NUS
 Stock
  

USD 43.29  0.60  1.37%   

  Director
Mr. Daniel W. Campbell is the Lead Independent Director of Nu Skin Enterprises, Inc
Age: 65  Director Since 1997      
801 345 1000  https://www.nuskin.com
Campbell was a Managing General Partner of EsNet, Ltd., a privately held investment company, since 1994. He has served on the Utah State Board of Regents for Higher Education since 2010 and served as its Vice Chair from 2012 to 2014 and as Chair from 2014 to 2018. From 1992 to 1994, Mr. Campbell was the Senior Vice President and Chief Financial Officer of WordPerfect Corporationrationrationration, a software company, and prior to that was a partner of Price Waterhouse LLP. He received a B.S. degree from Brigham Young University.

Daniel Campbell Latest Insider Activity

Tracking and analyzing the buying and selling activities of Daniel Campbell against Nu Skin stock is an integral part of due diligence when investing in Nu Skin. Daniel Campbell insider activity provides valuable insight into whether Nu Skin is net buyers or sellers over its current business cycle. Note, Nu Skin insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nu Skin'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Nu Skin Management Efficiency

Nu Skin Enterprises has Return on Asset of 9.46 % which means that on every $100 spent on asset, it made $9.46 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 16.3 %, implying that it generated $16.3 on every 100 dollars invested. Nu Skin management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/30/2022, Return on Investment is likely to grow to 30.63. Also, Return on Average Assets is likely to grow to 13.76. Nu Skin Revenue to Assets are relatively stable at the moment as compared to the past year. Nu Skin reported last year Revenue to Assets of 1.52. As of 06/30/2022, Net Current Assets as percentage of Total Assets is likely to grow to 24.00, while Current Assets are likely to drop slightly above 739.6 M.
The company has 503.78 M in debt with debt to equity (D/E) ratio of 0.55, which is OK given its current industry classification. Nu Skin Enterprises has a current ratio of 1.62, which is typical for the industry and considered as normal. Debt can assist Nu Skin until it has trouble settling it off, either with new capital or with free cash flow. So, Nu Skin's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nu Skin Enterprises sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nu Skin to invest in growth at high rates of return. When we think about Nu Skin's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Judith McHaleRalph Lauren Corp
2011
Joyce BrownRalph Lauren Corp
2001
Nelson PeltzProcter Gamble
2018
Cathleen BenkoNike Inc
2018
John ConnorsNike Inc
2005
Juan FiguereoPhillips-Van Heusen Corp
2011
Dina DublonPepsico
2005
Ian CookPepsico
2013
James McNerneyProcter Gamble
2007
Francis BlakeProcter Gamble
2015
William JohnsonPepsico
2015
Olden LeeStarbucks Corp
2010
Satya NadellaStarbucks Corp
2017
Debra OlerPool Corp
2018
Myron UllmanStarbucks Corp
2018
Margaret WhitmanProcter Gamble
2011
Johnathan RodgersNike Inc
2006
Mathias DopfnerNetflix
2018
Myrtle PotterRite Aid Corp
N/A
Frank SavageRite Aid Corp
N/A
Michael ReganRite Aid Corp
2011
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah. Nu Skin operates under Household Personal Products classification in the United States and is traded on New York Stock Exchange. It employs 4600 people. Nu Skin Enterprises (NUS) is traded on New York Stock Exchange in USA and employs 4,600 people.

Nu Skin Enterprises Leadership Team

Elected by the shareholders, the Nu Skin's board of directors comprises two types of representatives: Nu Skin inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nu Skin. The board's role is to monitor Nu Skin's management team and ensure that shareholders' interests are well served. Nu Skin's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nu Skin's outside directors are responsible for providing unbiased perspectives on the board's policies.
Nevin Andersen, Independent Director
Scott Pond, Director - Investor Relations
Mark Lawrence, Chief Financial Officer, Executive Vice President
D Dorny, Executive Vice President, General Counsel, Secretary
Ritch Wood, CFO, Principal Accounting Officer and VP
Daniel Campbell, Lead Independent Director
Edwina Woodbury, Independent Director
Zhequing Shen, Director
Chayce Clark, Executive Vice President General Counsel
Joseph Chang, Executive Vice President - Product Development, Chief Scientific Officer
Truman Hunt, CEO and President and Director
Laura Nathanson, Independent Director
Steven Lund, Executive Chairman of the Board
Matthew Dorny, VP, General Counsel and Secretary
Emma Battle, Director
Connie Tang, Executive Vice President Chief Global Growth & customer Experience Officer
Thomas Pisano, Independent Director
Neil Offen, Independent Director
Scott Schwerdt, President - Americas Region
Zheqing Shen, Independent Director
Andrew Lipman, Independent Director
James Thomas, Chief Accounting Officer
Ryan Napierski, President, Chief Executive Officer, Director

Nu Skin Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nu Skin a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Nu Skin without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bollinger Bands Now

   

Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Nu Skin Enterprises using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Nu Skin Enterprises information on this page should be used as a complementary analysis to other Nu Skin's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Nu Skin Stock analysis

When running Nu Skin Enterprises price analysis, check to measure Nu Skin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nu Skin is operating at the current time. Most of Nu Skin's value examination focuses on studying past and present price action to predict the probability of Nu Skin's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nu Skin's price. Additionally, you may evaluate how the addition of Nu Skin to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Is Nu Skin's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nu Skin. If investors know Nu Skin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nu Skin listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.16
Market Capitalization
2.3 B
Quarterly Revenue Growth YOY
-0.11
Return On Assets
0.0916
Return On Equity
0.15
The market value of Nu Skin Enterprises is measured differently than its book value, which is the value of Nu Skin that is recorded on the company's balance sheet. Investors also form their own opinion of Nu Skin's value that differs from its market value or its book value, called intrinsic value, which is Nu Skin's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nu Skin's market value can be influenced by many factors that don't directly affect Nu Skin's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nu Skin's value and its price as these two are different measures arrived at by different means. Investors typically determine Nu Skin value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nu Skin's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.